Lucitanib for the treatment of HR+HER2-metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial

被引：0

作者：

Hui, R. ^{[1
,2
]}

Pearson, A. ^{[3
]}

Cortes Castan, J.

Campbell, C. ^{[4
,5
]}

Poirot, C. ^{[6
]}

Azim, H. A., Jr. ^{[7
]}

Fumagalli, D. ^{[8
]}

Lambertini, M. ^{[9
]}

Daly, F. ^{[4
,5
]}

Arahmani, A. ^{[8
]}

Perez-Garcia, J. ^{[10
]}

Aftimos, P. G. ^{[11
]}

Bedard, P. ^{[12
]}

Xuereb, L. ^{[6
]}

Loibl, S. ^{[13
]}

Loi, S. ^{[14
]}

Pierrat, M-J. ^{[5
,6
]}

Turner, N. C. ^{[15
,16
]}

Andre, F. ^{[17
]}

Curigliano, G. ^{[18
]}

机构：

[1] Westmead Hosp, Dept Med Oncol, Sydney, NSW, Australia

[2] Univ Sydney, Sydney, NSW, Australia

[3] Inst Canc Res, Breast Canc Now Res Ctr, London, England

[4] Vall dHebron Univ Hosp, IOB Inst Oncol, Barcelona, Spain

[5] Frontier Sci Scotland, Kingussie, Scotland

[6] Inst Rech Int Servier, Suresnes, France

[7] Amer Univ Beirut, Internal Med, Beirut, Lebanon

[8] Breast Int Grp, Sci Dept, Brussels, Belgium

[9] Inst Jules Bordet, Dept Med, Brussels, Belgium

[10] Vall dHebron Inst Oncol VHIO, Dept Oncol, Barcelona, Spain

[11] Inst Jules Bordet, Med Oncol, Brussels, Belgium

[12] Univ Hlth Network, Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada

[13] German Breast Grp Forschungs GmbH, GBG, Neu Isenburg, Germany

[14] Peter MacCallum Canc Ctr, Div Res, Translat Breast Canc Genom Lab, Melbourne, Vic, Australia

[15] Royal Marsden Hosp, Toby Robins Breast Canc Res Ctr, London, England

[16] Inst Canc Res, London, England

[17] Gustave Roussy Canc Campus, Dept Med Oncol, Breast Canc Unit, Villejuif, France

[18] Ist Europeo Oncol, Early Drug Dev Innovat Therapies Div, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

289PD

引用

页码：93 / 93

页数：1